Found: 2
Select item for more details and to access through your institution.
Combined treatment with FABP4 inhibitor ameliorates rosiglitazone‐induced liver steatosis in obese diabetic db/db mice.
- Published in:
- Basic & Clinical Pharmacology & Toxicology, 2021, v. 129, n. 3, p. 173, doi. 10.1111/bcpt.13621
- By:
- Publication type:
- Article
Exogenous FABP4 interferes with differentiation, promotes lipolysis and inflammation in adipocytes.
- Published in:
- Endocrine (1355008X), 2020, v. 67, n. 3, p. 587, doi. 10.1007/s12020-019-02157-8
- By:
- Publication type:
- Article